当前位置：
X-MOL 学术
›
Hum. Gene Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
An Overview of Cell and Gene Therapy Development in China
Human Gene Therapy ( IF 3.9 ) Pub Date : 2022-01-17 , DOI: 10.1089/hum.2021.126 Yitong Wang 1 , Tingting Qiu 1 , Shuyao Liang 1 , Mondher Toumi 1
Human Gene Therapy ( IF 3.9 ) Pub Date : 2022-01-17 , DOI: 10.1089/hum.2021.126 Yitong Wang 1 , Tingting Qiu 1 , Shuyao Liang 1 , Mondher Toumi 1
Affiliation
China, the first country worldwide to approve a gene therapy in 2003, almost lost the advantage for a head start in cell and gene therapy (CGT) development due to a lack of clear and strict regulatory frameworks. The rapid advancements of CGTs' development worldwide as well as their therapeutic potential have triggered the government to conduct a spate of regulatory reforms to promote normative development of CGTs in China. Encouraged by policy support, the remarkable progress for CGTs in China has been observed over the past few years, thereby catapulting China back into the forefront of CGTs worldwide. This article aims to provide an overview of regulatory reforms, the current development landscape of CGTs, as well as key contributors and challenges for CGT development in China.
更新日期：2022-01-20
京公网安备 11010802027423号